Establishment Labs to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
minimally invasivemedical
Medical procedures described as minimally invasive use small cuts, flexible tubes or tiny cameras to treat or diagnose problems with far less cutting than traditional surgery — like using a keyhole instead of tearing down a wall. Investors care because these approaches can shorten hospital stays, lower complication rates and change equipment and reimbursement needs, which can speed adoption and reshape market demand for devices, supplies and services.
irbregulatory
An Institutional Review Board (IRB) is an independent committee that reviews and approves medical and behavioral research involving people to ensure safety, informed consent, and ethical treatment—think of it as a safety inspector for studies. For investors, IRB decisions matter because their approval or requests for changes can speed up, delay, or halt clinical trials and other studies, directly affecting timelines, costs, and the value of companies developing treatments.
pivotal studymedical
A pivotal study is a large, definitive clinical trial designed to show whether a medical product works and is safe enough for regulators to approve and for doctors to use. Think of it as the final exam that determines whether a drug or device moves from testing into the market; its results can dramatically change a company’s approval chances, future sales prospects, and therefore its stock value.
mri conditionalmedical
MRI conditional is a regulatory label for a medical device or implant that means it can safely enter an MRI scanner only when certain, clearly specified conditions are met (such as scanner strength, device orientation or imaging settings). Like a gadget that works only underwater to a set depth, the label matters to investors because it affects clinical adoption, product competitiveness, regulatory clearance and potential liability: broad or restrictive conditions can materially influence sales and market access.
radio-frequency technologytechnical
Radio-frequency technology uses invisible radio waves to send, receive, or heat energy for communication, sensing, or medical and industrial procedures — think of it as sending ripples through the air or tissue to carry signals or produce controlled effects. Investors watch it because its performance, regulatory approvals, patents and compatibility with standards determine product adoption, recurring revenue and competitive advantage, much like a highway that enables new businesses to reach customers.
rfidtechnical
RFID, or Radio Frequency Identification, is a technology that uses radio waves to automatically identify and track objects, animals, or people. It involves small tags or chips that emit signals when scanned, similar to a barcode but without needing direct line-of-sight. For investors, RFID enhances supply chain efficiency and inventory management, potentially reducing costs and improving business operations.
biosensormedical
A biosensor is a device that detects biological signals—such as proteins, DNA, or metabolites—and converts them into readable electronic or visual data, like a smoke detector that senses a problem and triggers a readable alert. For investors it matters because biosensors can enable faster, cheaper, and more frequent medical tests or environmental monitoring, creating sales, recurring consumable demand, and potential regulatory milestones that can materially affect a company’s revenue and valuation.
iso13485:2016regulatory
ISO 13485:2016 is an international standard that specifies what a company must do to manage quality for medical devices and related services — think of it as a detailed recipe and checklist to make sure devices are designed, made and controlled consistently and safely. For investors, certification signals lower regulatory and operational risk, smoother market access and a reduced chance of costly recalls or compliance fines, which can protect revenue and company value.
NEW YORK--(BUSINESS WIRE)--
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 44th Annual J.P Morgan Healthcare Conference on January 14, 2026 at 9:45 a.m. PT.
A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. Archived versions of the webcasts will be available on the same website following the completion of the events.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the Company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé®, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zenº™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com.
